Cryptochrome 2 stabilization alleviates psoriasis by inhibiting keratinocyte hyperproliferation and inflammation

Area of Science:

• Dermatology
• Immunology
• Chronobiology

Background:

• Psoriasis is a chronic inflammatory skin disease with abnormal keratinocyte proliferation and immune imbalance.
• Cryptochrome 2 (CRY2), a regulator of circadian rhythms, is linked to inflammation, but its role in psoriasis is unclear.

Purpose of the Study:

• To investigate the role of CRY2 in psoriasis pathogenesis.
• To evaluate CRY2 as a therapeutic target and KL001 as a potential treatment.

Main Methods:

• Analysis of CRY2 expression in psoriasis patients.
• Utilized cellular, murine, and in vitro human tissue models.
• Assessed the effects of CRY2 deficiency and KL001 treatment on psoriatic phenotypes.

Main Results:

• CRY2 expression is significantly downregulated in psoriasis and restored by biological therapy.
• CRY2 deficiency worsens inflammation and hyperproliferation via ERK1/2 signaling.
• KL001 treatment ameliorated key psoriasis features like epidermal thickening and chemokine production.

Conclusions:

• CRY2 plays a critical role in psoriasis development.
• CRY2 is a promising therapeutic target for psoriasis.
• KL001 represents a potential adjunctive therapy for psoriasis.